Improved Biorefinery for the Production of Ethanol, Chemicals, Animal Feed and Biomaterials From Sugar Cane

The Audubon Sugar Institute (ASI) of Louisiana State University’s Agricultural Center (LSU AgCenter) and MBI International (MBI) sought to develop technologies that will lead to the development of a sugar-cane biorefinery, capable of supplying fuel ethanol from bagasse. Technology development focused on the conversion of bagasse, cane-leaf matter (CLM) and molasses into high value-added products that included ethanol, specialty chemicals, biomaterials and animal feed; i.e. a sugar cane-based biorefinery. The key to lignocellulosic biomass utilization is an economically feasible method (pretreatment) for separating the cellulose and the hemicellulose from the physical protection provided by lignin. An effective pretreatment disrupts physical barriers, cellulose crystallinity, and the association of lignin and hemicellulose with cellulose so that hydrolytic enzymes can access the biomass macrostructure (Teymouri et al. 2004, Laureano-Perez, 2005). We chose to focus on alkaline pretreatment methods for, and in particular, the Ammonia Fiber Expansion (AFEX) process owned by MBI. During the first two years of this program a laboratory process was established for the pretreatment of bagasse and CLM using the AFEX process. There was significant improvement of both rate and yield of glucose and xylose upon enzymatic hydrolysis of AFEX-treated bagasse and CLM compared with untreated material. Because of reactor size limitation, several other alkaline pretreatment methods were also co-investigated. They included, dilute ammonia, lime and hydroxy-hypochlorite treatments. Scale-up focused on using a dilute ammonia process as a substitute for AFEX, allowing development at a larger scale. The pretreatment of bagasse by an ammonia process, followed by saccharification and fermentation produced ethanol from bagasse. Simultaneous saccharification and fermentation (SSF) allowed two operations in the same vessel. The addition of sugarcane molasses to the hydrolysate/fermentation process yielded improvements beyond what was expected solely from the addition of sugar. In order to expand the economic potential for building a biorefinery, the conversion of enzyme hydrolysates of AFEX-treated bagasse to succinic acid was also investigated. This program established a solid basis for pre-treatment of bagasse in a manner that is feasible for producing ethanol at raw sugar mills

Transversity and Collins Fragmentation Functions: Towards a New Global Analysis

A new, preliminary global analysis of the experimental data on azimuthal asymmetries in SIDIS from HERMES and COMPASS collaborations, and in e+e- --> h_1 h_2 X processes from the BELLE collaboration, is performed. The new data allow for a more precise determination of the Collins fragmentation function and of the transversity distribution function for $u$ and $d$ quarks, in comparison with the results of our previous analysis. Estimates for the single spin asymmetry A_UT^{\sin(\phi_h + \phi_S)} at JLab and COMPASS, operating on a transversely polarized proton target, are presented.Comment: 4 pages, 4 figures. To appear in the proceedings of the XVI International Workshop on Deep Inelastic Scattering and Related Subjects, DIS 2008, London, U.K., 7-11 April, 200

withdrawn 2017 hrs ehra ecas aphrs solaece expert consensus statement on catheter and surgical ablation of atrial fibrillation

n/

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Sugar-Based Ethanol Biorefinery: Ethanol, Succinic Acid and By-Product Production

The work conducted in this project is an extension of the developments itemized in DE-FG-36-04GO14236. This program is designed to help the development of a biorefinery based around a raw sugar mill, which in Louisiana is an underutilized asset. Some technical questions were answered regarding the addition of a biomass to ethanol facility to existing sugar mills. The focus of this work is on developing technology to produce ethanol and valuable by-products from bagasse. Three major areas are addressed, feedstock storage, potential by-products and the technology for producing ethanol from dilute ammonia pre-treated bagasse. Sugar mills normally store bagasse in a simple pile. During the off season there is a natural degradation of the bagasse, due to the composting action of microorganisms in the pile. This has serious implications if bagasse must be stored to operate a bagasse/biorefinery for a 300+ day operating cycle. Deterioration of the fermentables in bagasse was found to be 6.5% per month, on pile storage. This indicates that long term storage of adequate amounts of bagasse for year-round operation is probably not feasible. Lignin from pretreatment seemed to offer a potential source of valuable by-products. Although a wide range of phenolic compounds were present in the effluent from dilute ammonia pretreatment, the concentrations of each (except for benzoic acid) were too low to consider for extraction. The cellulosic hydrolysis system was modified to produce commercially recoverable quantities of cellobiose, which has a small but growing market in the food process industries. A spin-off of this led to the production of a specific oligosaccharide which appears to have both medical and commercial implications as a fungal growth inhibitor. An alternate use of sugars produced from biomass hydrolysis would be to produce succinic acid as a chemical feedstock for other conversions. An organism was developed which can do this bioconversion, but the economics of succinic acid production were such that it could not compete with current commercial practice. To allow recovery of commercial amounts of ethanol from bagasse fermentation, research was conducted on high solids loading fermentations (using S. cerevisiae) with commercial cellulase on pretreated material. A combination of SHF/SSF treatment with fed-batch operation allowed fermentation at 30% solids loading. Supplementation of the fermentation with a small amount of black-strap molasses had results beyond expectation. There was an enhancement of conversion as well as production of ethanol levels above 6.0% w/w, which is required both for efficient distillation as well as contaminant repression. The focus of fermentation development was only on converting the cellulose to ethanol, as this yeast is not capable of fermenting both glucose and xylose (from hemicellulose). In anticipation of the future development of such an organism, we screened the commercially available xylanases to find the optimum mix for conversion of both cellulose and hemicellulose. A different mixture than the spezyme/novozyme mix used in our fermentation research was found to be more efficient at converting both cellulose and hemicellulose. Efforts were made to select a mutant of Pichia stipitis for ability to co-ferment glucose and xylose to ethanol. New mutation technology was developed, but an appropriate mutant has not yet been isolated. The ability to convert to stillage from biomass fermentations were determined to be suitable for anaerobic degradation and methane production. An economic model of a current sugar factory was developed in order to provide a baseline for the cost/benefit analysis of adding cellulosic ethanol production

Compositional changes in sugarcane bagasse on low temperature, long-term diluted ammonia treatment

Sugarcane bagasse is the major by-product of the sugar industry. It has a great potential for the production of biofuels and chemicals due to its considerable amount of cellulose and hemicellulose. In this study, we investigated a simple and economic pretreatment process using dilute ammonia for the storage of sugarcane bagasse. Sugarcane bagasse was stored in 0, 0.03, and 0.3% (w/w) ammonium hydroxide in a closed bottle for 40 days at 30 degrees C under atmospheric pressure without any agitation or circulation. Samples were taken every 10 days and analyzed for changes on lignin, cellulose, hemicellulose composition, ammonia concentration, and microbial counts. Biomass storage for 40 days at 0.3% ammonium hydroxide removed 46% of lignin and retained 100% cellulose and 73% hemicellulose